<DOC>
	<DOCNO>NCT00997763</DOCNO>
	<brief_summary>The purpose study establish safety effectiveness coronary stenting Everolimus- Eluting stent compare Sirolimus-Eluting stent treatment de novo coronary stenosis patient diabetic patient .</brief_summary>
	<brief_title>Comparison Everolimus-Eluting Stent v Sirolimus-Eluting Stent Patients With DIABETES Mellitus</brief_title>
	<detailed_description>Diabetic patient often present unfavorable coronary anatomy small diffusely diseased vessel ( 1 ) exhibit exaggerated neointimal hyperplasia bare-metal stent ( BMS ) implantation compare nondiabetics ( 2 ) . Although drug-eluting stent ( DES ) implantation significantly reduce neointimal hyperplasia angiographic restenosis compare BMS diabetic patient ( 3 ) , presence diabetes mellitus ( DM ) still associate increase risk restenosis unfavorable clinical outcome era DES ( 4,5 ) . Recently , relative efficacy sirolimua-eluting stent ( SES ) paclitaxel-eluting stent ( PES ) patient DM evaluate randomized registry study ( 6-10 ) . The present study , ESSENCE-DIABETES Study , compare 8-month angiographic 1-year clinical outcome patient diabetes mellitus treat sirolimus-eluting stent ( CYPHER ) everolimus-eluting stent ( XIENCE V )</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Diabetic patient angina document ischemia patient document silent ischemia Patients eligible intracoronary stenting Age &gt; 18 year , &lt; 75 age De novo lesion Percent diameter stenosis ≥50 % Reference vessel size ≥ 2.5 mm visual estimation History bleed diathesis coagulopathy Pregnant state Known hypersensitivity contraindication contrast agent heparin Limited lifeexpectancy ( less 1 year ) Acute ST elevation myocardial infarction admission Characteristics lesion 1 . Left main disease 2 . Instent restenosis 3 . Graft vessels Hematological disease ( Neutropenia &lt; 3000/mm3 , Thrombocytopenia &lt; 100,000/mm3 ) Hepatic dysfunction , liver enzyme ( ALT AST ) elevation ≥ 3 time normal Renal dysfunction , creatinine ≥ 2.0mg/dL Contraindication aspirin , clopidogrel cilostazol Left ventricular ejection fraction &lt; 30 % Patients actively participate another drug device investigational study , complete primary endpoint followup period . Noncardiac comorbid condition present life expectancy &lt; 1 year may result protocol noncompliance ( per site investigator 's medical judgment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>stenting , XIENCE V , CYPHER</keyword>
</DOC>